CoChat
Sign Up
Cited by 163Cardiac electrophysiology and arrhythmiasPharmacovigilance and Adverse Drug ReactionsCystic Fibrosis Research Advances

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Macrolide Antibiotics and the Risk of Cardiac Arrhythmias

Open access
Albert, Richard K., Schuller, Joseph L.·2014·American Journal of Respiratory and Critical Care Medicine
DOI 10.1164/rccm.201402-0385ciPMC PMC4061901
Open this paper in CoChat — free account

Abstract

Randomized, controlled trials have demonstrated that chronic therapy with macrolide antibiotics reduces the morbidity of patients with cystic fibrosis, non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, and nontuberculous mycobacterial infections. Lower levels of evidence indicate that chronic macrolides are also effective in treating patients with panbronchiolitis, bronchiolitis obliterans, and rejection after lung transplant. Macrolides are known to cause torsade des pointes and other ventricular arrhythmias, and a recent observational study prompted the FDA to strengthen the Warnings and Precautions section of azithromycin drug labels. This summary describes the electrophysiological effects of macrolides, reviews literature indicating that the large majority of subjects experiencing cardiac arrhythmias from macrolides have coexisting risk factors and that the incidence of arrhythmias in absence of coexisting risk factors is very low, examines recently published studies describing the relative risk of arrhythmias from macrolides, and concludes that this risk has been overestimated and suggests an approach to patient evaluation that should reduce the relative risk and the incidence of arrhythmias to the point that chronic macrolides can be used safely in the majority of subjects for whom they are recommended.

Overview

Integrity signals

Registry

Crossref · 10.1164/rccm.201402-0385ci

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 89 references

Research works printed but not linked: 1

  1. Raschi, 2013, Macrolides and torsadogenic risk: emerging issues from the FDA pharmacovigilance database, J Pharmacovigilance, 1, 104

Cited by

Sorted by citations

Items 101–162 of 162

Related

See all

Metadata

Authors
Albert, R. K., & Schuller, J. L.
Affiliations
Denver Health Medical Center (US)
Corresponding author
Albert, Richard K.
ORCID
Albert, Richard K.
Venue
American Journal of Respiratory and Critical Care Medicine
Publisher
Oxford University Press (OUP)
Published
2014-05
Volume
189
Issue
10
Pages
1173-1180
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
DOI
10.1164/rccm.201402-0385ci
PMC
PMC4061901
OpenAlex
W2134495308
Cited by
163
References
89
Citations by year
2026: 10 · 2025: 12 · 2024: 9 · 2023: 7 · 2022: 12 · 2021: 8 · 2020: 23 · 2019: 15 · 2018: 12 · 2017: 17 · 2016: 8 · 2015: 22 · 2014: 7
FWCI
2.90
Type
journal article
Language
en
Open access
Licence
academic.oup.com/pages/standard-publication-reuse-rights (vor)
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Keywords
macrolide antibiotics, cardiac arrhythmias, torsades de pointes, ventricular arrhythmias, azithromycin, drug safety, risk factors, cystic fibrosis, non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, nontuberculous mycobacterial infection, lung transplant rejection, bronchiolitis obliterans, electrophysiological effects
MeSH terms
Anti-Bacterial Agents, Arrhythmias, Cardiac, Cystic Fibrosis, Heart Conduction System, Humans, Risk Factors, Randomized Controlled Trials as Topic, Azithromycin, Macrolides, Pulmonary Disease, Chronic Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review